Oppenheimer Maintains Outperform on Teladoc Health, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Michael Wiederhorn maintains an Outperform rating on Teladoc Health (NYSE:TDOC) but lowers the price target from $21 to $17.
August 01, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Michael Wiederhorn maintains an Outperform rating on Teladoc Health but lowers the price target from $21 to $17.
The Outperform rating suggests a positive outlook, but the lowered price target indicates some concerns about near-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100